Phospho-CDH5 (Tyr731) Antibody

說明書

中文名稱：

磷酸化-CDH5 (Tyr731)兔多克隆抗體
貨號：

CSB-PA868788
規(guī)格：

￥2454
圖片：
Western blot analysis of extracts from HepG2 cells treated with Na3VO4 using Phospho-VE-Cadherin (Tyr731) antibody.The lane on the right is treated with the antigen-specific peptide.
其他：

產(chǎn)品詳情
產(chǎn)品評價(jià)
相關(guān)產(chǎn)品
靶點(diǎn)詳情

產(chǎn)品詳情

產(chǎn)品名稱：

Rabbit anti-Homo sapiens (Human) CDH5 Polyclonal antibody
Uniprot No.：

P33151
基因名：

CDH5
別名：

CDH5; Cadherin-5; 7B4 antigen; Vascular endothelial cadherin; VE-cadherin; CD antigen CD144
宿主：

Rabbit
反應(yīng)種屬：

Human,Mouse
免疫原：

Peptide sequence around phosphorylation site of Tyrosine731 (H-I-Y(p)-G-Y) derived from Human VE-Cadherin.
免疫原種屬：

Homo sapiens (Human)
克隆類型：

Polyclonal
純化方式：

Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatogramphy usi
濃度：

It differs from different batches. Please contact us to confirm it.
產(chǎn)品提供形式：

Liquid
應(yīng)用范圍：

ELISA,WB

推薦稀釋比：

Application	Recommended Dilution
WB	1:500-1:1000

Protocols：

ELISA Protocol
Western Blotting (WB) Protocol
儲(chǔ)存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產(chǎn)品評價(jià)

靶點(diǎn)詳情

功能：

Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types. This cadherin may play a important role in endothelial cell biology through control of the cohesion and organization of the intercellular junctions. It associates with alpha-catenin forming a link to the cytoskeleton. Acts in concert with KRIT1 and PALS1 to establish and maintain correct endothelial cell polarity and vascular lumen. These effects are mediated by recruitment and activation of the Par polarity complex and RAP1B. Required for activation of PRKCZ and for the localization of phosphorylated PRKCZ, PARD3, TIAM1 and RAP1B to the cell junction.
基因功能參考文獻(xiàn)：
1. VE-cadherin internalization from tensile adherens junctions is inhibited by Pacsin2 protein. PMID: 27417273
2. It was found that the levels of integrin alpha1 and VE-cadherin mRNA increased during co-culturing of activated endothelium cells with mesenchymal stromal cells. PMID: 29504106
3. Endothelial flow mechanotransduction through the junctional complex is mediated by a specific pool of VE-cadherin that is phosphorylated on cytoplasmic tyrosine Y658 and bound to LGN. PMID: 28712573
4. BMP4 controls leukocyte recruitment through a VE-cadherin-dependent mechanism PMID: 28755278
5. hsa-miR-6086 is induced by TNFalpha and mediates TNFalpha-induced HUVEC growth inhibition through downregulating CDH5 expression. Hence, hsa-miR-6086 might be a new target for treating TNFalpha-induced endothelial dysfunction. PMID: 29605606
6. activation of PAR2 compromises the vascular endothelial barrier function by suppressing the expression of Ve-cadherin. PMID: 28485540
7. C. pneumoniae infection promotes monocyte transendothelial migration by increasing vascular endothelial cell permeability via the tyrosine phosphorylation and internalization of VE-cadherin in vascular endothelial cells. PMID: 29462613
8. The study shows a VE-cadherin-mediated cell dynamics and an endothelial-dependent proliferation in a differentiation-dependent manner. PMID: 29143117
9. VE-cadherin activated cell stiffening depends on substrate stiffness. Force loading VE-cadherin receptors triggers cell-matrix junction remodeling. Local, VE-cadherin force transduction signals at the cell level do not alter the mechanical balance of endothelial colonies. PMID: 28624707
10. HIF-2alpha and VM were overexpressed in pancreatic cancer tissues and were associated with poor pathological characteristics. HIF-2alpha contributes to VM formation by regulating the expression of VE-cadherin through the binding of the transcription factor Twist1 to the promoter of VE-cadherin in pancreatic cancer both in vitro and in vivo. PMID: 28599281
11. These findings support a general role for VE-cadherin and other RGD cadherins as critical regulators of lung and liver metastasis in multiple solid tumours. These results pave the way for cadherin-specific RGD targeted therapies to control disseminated metastasis in multiple cancers. PMID: 27966446
12. This study demonstrated that changes in gene expression of CDH5 and CLDN5 due to shear stress within individual differentiations also revealed no trend. PMID: 28774343
13. Data suggest that cadherin 5 (CDH5) may play a key role in hematogenous recurrence of advanced gastric cancer and may be a viable treatment target. PMID: 29187459
14. The present study investigated the interplay of VEGF-A165a isoform, the anti-angiogenic VEGF-A165b, placental growth factor (PIGF) and their receptors, VEGFR1 and VEGFR2.on junctional occupancy of VE-cadherin and macromolecular leakage in human endothelial monolayers and the perfused placental microvascular bed. PMID: 29054861
15. These results suggest that SHP-2-via association with ICAM-1-mediates ICAM-1-induced Src activation and modulates VE-cadherin switching association with ICAM-1 or actin, thereby negatively regulating neutrophil adhesion to endothelial cells and enhancing their transendothelial migration. PMID: 28701303
16. CDH5 and FABP1 expression levels were both elevated in drug-induced liver injury. PMID: 27224670
17. Varenicline promotes HUVEC migration by lowering VE-cadherin expression due to activated ERK/p38/JNK signaling through alpha7 nAChR. These processes probably contribute to varenicline-aggravated atherosclerotic plaque. PMID: 28842382
18. Plakoglobin maintains the integrity of vascular endothelial cell junctions and regulates VEGF-induced phosphorylation of VE-cadherin PMID: 28158602
19. Endothelial Tspan5- and Tspan17-ADAM10 complexes may regulate inflammation by maintaining normal VE-cadherin expression and promoting T lymphocyte transmigration. PMID: 28600292
20. Study found that high VE-cadherin gene expression levels were associated with low expression of miR-27b and that the latter directly bound to its 3'UTR to regulate its expression. PMID: 28396577
21. Cells in high glucose for 7 days showed a significant decrease in mRNA expression of CD31 and VE-cadherin, and a significant increase in that of alpha-SMA and collagen I. PMID: 28347704
22. AngII could induce pulmonary injury by triggering endothelial barrier injury, and such process may be related to the dephosphorylation of Y685-VE-cadherin and the endothelial skeletal rearrangement PMID: 28119542
23. Breast cancer-secreted miR-939 downregulates VE-cadherin and destroys the barrier function of endothelial monolayers. PMID: 27693459
24. EGFR genes are associated with overexpression of CDH5 through increased phosphorylation of EGFR and downstream Akt pathways. PMID: 27362942
25. We found that patients with chronic spontaneous urticaria (CSU) had significantly higher CDH5 serum levels compared with patients with atopic dermatitis and control subjects. Moreover, serum levels ofCDH5 were closely associated with the severity of CSU. PMID: 28583263
26. Results indicate that the posthemorrhagic shock mesenteric lymph in vitro increases the cellular permeability of human umbilical vein endothelial cells through suppression of F-actin and VE-cadherin. PMID: 27338534
27. CMTM3 mediates cell-cell adhesion at adherens junctions and contributes to the control of vascular sprouting by regulation VE-cadherin turnover. PMID: 28428220
28. Serum CDH5 correlates to poorer survival in patient with hormone-refractory metastatic breast cancer. PMID: 28056463
29. Lateral accumulation of cadherin fingers in follower cells precedes turning, and increased actomyosin contractility can initiate cadherin finger extension as well as engulfment by a neighbouring cell, to promote follower behaviour. PMID: 27842057
30. the conserved targeting of VE-cadherin by miR-22 regulates endothelial inflammation, tissue injury, and angiogenesis. PMID: 28112401
31. High serum VE-cadherin expression is associated with non-alcoholic fatty liver disease. PMID: 26959535
32. CDH5 may play a key role in the progression or metastasis of differentiated-type gastric cancer and serve as a target for its treatment. PMID: 27466381
33. PDE4D acts to allow cAMP-elevating agents to regulate VECADs' role as a sensor of flow-associated fluid shear stress (FSS)-encoded information in arterial endothelial cells. PMID: 26658094
34. Data suggest that the microRNA miR-27a-3p-mediated down-regulation of VE-cadherin and inhibition of epithelial-mesenchymal transition may be essential for Twist-1 to induce tumor metastasis and vasculogenic mimicry (VM). PMID: 26980408
35. Quaking directly binds to the mRNA of VE-cadherin and beta-catenin and can induce mRNA translation mediated by the 3'UTR of these genes. PMID: 26905650
36. Prophylactic UTI maintains the endothelial barrier function, increases VE-cadherin expression, and inhibits the phosphorylation of VE-cadherin at Tyr658 under inflammatory conditions PMID: 26681130
37. S-nitrosylation regulates endothelial cell VE-cadherin phosphorylation and internalization in microvascular permeability. PMID: 26921435
38. Data indicate that monoclonal antibody (mAb) against vascular endothelial cadherin 5 (VECDH5) has good binding ability and specificity. PMID: 26728385
39. Rab11a/Rab11 family-interacting protein 2-mediated VE-cadherin recycling is required for formation of adherens junctions and restoration of vascular endothelial barrier integrity. PMID: 26663395
40. our data show the importance of spatio-temporal regulation of the actin cytoskeleton through Trio and Rac1 at VE-cadherin-based cell-cell junctions in the maintenance of the endothelial barrier. PMID: 26116572
41. ankyrin-G associates with and inhibits the endocytosis of VE-cadherin cis dimers. PMID: 26574545
42. VE-cadherin complexes are central force transducers in endothelial barrier in response to force. PMID: 25663699
43. Demonstrate that TrkB protects endothelial integrity during atherogenesis by promoting Ets1-mediated VE-cadherin expression and plays a previously unknown protective role in the development of coronary artery disease. PMID: 25633318
44. homophilic interactions of VE-cadherin stabilize it at cell borders and prevent entry into the lateral border recycling compartment. PMID: 25501813
45. Breast cancer cell incorporation into the vascular endothelium initiates by dislocating VE-cadherin at endothelial cell junctions. PMID: 25275457
46. HIF-1alpha may modulate vascular mimicry in esophageal squamous cell carcinoma by regulating VE-cadherin expression. PMID: 25548487
47. Girdin regulates the trafficking of VE-cadherin in synergy with R-Ras. PMID: 25869066
48. preeclampsia does not significantly affect vascular growth or the expression of endothelial junction proteins in human placentas PMID: 25362142
49. MRTF-A and p300 activated the transcription of VE-cadherin gene by enhancing acetylation of histones. PMID: 25746323
50. the transmembrane domain of VE-cadherin mediates an essential adapter function by binding directly to the transmembrane domain of VEGFR2, as well as VEGFR3. PMID: 25800053
顯示更多

收起更多
亞細(xì)胞定位：

Cell junction. Cell membrane; Single-pass type I membrane protein.
組織特異性：

Endothelial tissues and brain.
數(shù)據(jù)庫鏈接：

HGNC: 1764

OMIM: 601120

KEGG: hsa:1003

STRING: 9606.ENSP00000344115

UniGene: Hs.76206

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human